Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Quoin Pharmaceuticals (NASDAQ: QNRX) spikes over 50% after rapamycin breakthrough in rare disease program Quoin Pharmaceuticals (NASDAQ: QNRX) stock surged over 50% after achieving key rapamycin delivery targets. Find out how this positions its rare disease pipeline. byVenkateshNovember 11, 2025